Clinical trials: Deglutition Disorder
GERD
A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects
A Study to compare Pharmacokinetics, Pharmacodynamics and safety of CKD-381 and D027 in healty subjects
- Trial name
- NCT03211143
- Testing
- CKD-381, Nexium
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastroesophageal Reflux Disease (GERD)
Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus, causing irritation and inflammation.
- Trial name
- ARMOR (NCT06984484)
- Testing
- Afluxin®
- Where
- 7 sites in Italy
- Volunteers
- 208 people
- Sponsor
- Devintec Sagl
Dysphagia, Dysphagia, Oral Phase
Dose-response Effect of the Thickener Tsururinko Quickly
Thickening fluids are a valid therapeutic strategy to improve safe swallowing in OD. The aim of this study is to assess the percentage of safe swallowing at different viscosity levels thickened with Tsururinko Quickly.
- Conditions
- Dysphagia, Dysphagia, Oral Phase, Dysphagia, Oropharyngeal, Dysphagia, Esophageal
- Trial name
- 58/19 (NCT04565587)
- Testing
- Xanthan-gum based thickener
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Morinaga Milk Industry Co., LTD
GERD
Asociación Española de Gastroenterologia (Spanish Gastroenterology Association) Gastroesophageal Reflux Disease Guideline - Prospective Study
To evaluate symptomatic outcome and HRQoL in GERD patients treated following a new CP Guideline.
- Trial name
- Prospect (NCT00697008)
- Where
- 29 sites in Spain
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Gastro Esophageal Reflux Disease
Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance (Encore)
Study Hypothesis: This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes.
- Trial name
- NCT01788085
- Testing
- Bravo pH monitoring procedure
- Where
- Israel
- Sponsor
- Medtronic - MITG
Neurogenic Dysphonia, Neurogenic Dysphagia
Neurogenic Dysphonia/Dysphagia Registry
The Neurogenic Dysphonia/Dysphagia Registry is designed to be purely observational (i.e. non-interventional, exploratory). Patient data collected from the registry is expected to be consistent with any information which can be…
- Trial name
- StrongVoice (NCT02493491)
- Where
- 12 sites in United States
- Volunteers
- 146 people
- Sponsor
- Merz North America, Inc.
Stool Assessment, Skin Rash
GI Symptoms in Infants Fed Goat Milk-based Infant Formula
A cross-sectional observational survey was conducted in Brazil, Mexico, Russia, and The Netherlands by recruiting parents/legal guardians through social media.
- Conditions
- Stool Assessment, Skin Rash, Urticaria, Regurgitation
- Trial name
- NCT06755424
- Where
- Netherlands
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- Ausnutria Hyproca B.V.
Gastroesophageal Reflux Disease, GERD
Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn
- Trial name
- NCT00373334
- Testing
- nizatidine (axid)
- Where
- 26 sites in United States
- Volunteers
- 138 people
- Sponsor
- Braintree Laboratories
Gastroesophageal Reflux Disease
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the…
- Trial name
- RESTORE500 (NCT07004439)
- Testing
- RefluxStop™ implantation
- Where
- 5 sites in Germany, Spain
- Volunteers
- 500 people
- Sponsor
- Implantica CE Reflux Ltd.
Oesophageal Reflux, Gastric Reflux
Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux
A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and…
- Conditions
- Oesophageal Reflux, Gastric Reflux, Hyperactivity; Stomach
- Trial name
- AQUAA (NCT05060744)
- Testing
- Antacid, Control
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Uriach Consumer Healthcare
Gastroesophageal Reflux
A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn
The purpose of the study is to compare the pharmacodynamics (the way a drug works in the body) of rabeprazole and pantoprazole on intragastric acidity and esophageal acid exposure in gastroesophageal reflux disease (GERD)…
- Trial name
- NCT00237367
- Testing
- rabeprazole and pantoprazole
- Volunteers
- 52 people
- Sponsor
- PriCara, Unit of Ortho-McNeil, Inc.
Gastroesophageal Reflux Disease (GERD)
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.
- Trial name
- NCT05870163
- Testing
- RefluxStop implantation, Nissen fundoplication
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 2,500 people
- Sponsor
- Implantica CE Reflux Ltd.
Symptomatic Gastroespohageal Reflux Disease
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
Gastroesophageal Reflux Disease (GERD) is a common disorder caused by the reflux of gastric (stomach) acid into the esophagus. The exposure of the lining of the esophagus to the acid will cause damage to the esophagus over time.
- Trial name
- NCT00149851
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 832 people
- Sponsor
- Novartis
Gastro-oesophageal Reflux Disease
Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor
The aim of the present study was to evaluate the effect of a 6-weeks treatment of a CE-marked combination oral formulation of hyaluronic acid with chondroitin sulphate and aluminium hydroxide (GERDOFF®), in addition to proton…
- Trial name
- NCT03793556
- Testing
- GERDOFF® + Omeprazole, Omeprazole
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- SOFAR S.p.A.
Reflux, Heartburn
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
The aim of this project is to compare the GERD clinical outcomes in patients where a structured pathway using the GerdQ questionnaire is implemented compared with the clinical outcomes of those treated without this…
- Conditions
- Reflux, Heartburn, Regurgitation, Esophagitis
- Trial name
- NCT00842387
- Where
- 66 sites in Austria, Italy and 3 more
- Volunteers
- 2,370 people
- Sponsor
- AstraZeneca
Reflux Episodes
TLESR-impedance Study in Patients
The purpose of the study is to compare frequency and content of reflux episodes in patients with gastroesophageal reflux disease.
- Trial name
- NCT00743444
- Testing
- AZD3355
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.
- Trial name
- NCT04531475
- Testing
- X842, Lansoprazole
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastroesophageal Reflux Disease (GERD)
Endoscopic Full-Thickness Plication for the Treatment of GERD: Long-Term Multicenter Results
The purpose of this study was to gather long-term follow-up data on patients treated with the Plicator in a previous open-label multi-center study. Originally, 64 subjects were treated at seven U.S. sites.
- Trial name
- LTFU (NCT00587392)
- Testing
- NDO Full-thickness Plicator
- Where
- 7 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- NDO Surgical, Inc.
GERD
Novel Endoluminal Clinical TreAtment of Reflux
This is a prospective, multi-center, double-blind, crossover, randomized controlled trial designed to demonstrate the safety and efficacy of Aluvra for the treatment of GERD.
- Trial name
- NECTAR (NCT03090607)
- Testing
- Aluvra™, Saline
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Impleo Medical Inc.
Gastroesophageal Reflux
Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to provide additional information on safety and tolerability after multiple does of pantoprazole. Only patients who successfully completed the 3001B3-331 study (NCT00362609) or 3001B3-333 study…
- Trial name
- NCT00868296
- Testing
- pantoprazole
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 58 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer